Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...

Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...

Natural products have historically served as a vital source of chemotherapeutic agents, laying the foundation for many standard-of-care drugs. However, the ...